Quick Facts

• Adult Women and Adolescent Females: Used to address acute, uncomplicated infections of the bladder (cystitis) when caused by susceptible bacteria.
• Prophylaxis: May be utilized as a preventative measure for infection in adult men undergoing a prostate biopsy (transrectal procedure).
• Other Serious Infections (IV form): Reserved for treating more complicated or severe bacterial infections in various bodily systems when alternative treatment options are not suitable, based on specific clinical needs.

---

Fosfomicina Kern (containing the active substance fosfomycin) is an approved medication indicated for specific bacterial infections. Its primary use involves providing treatment for uncomplicated acute cystitis (bladder infection) in adult women and adolescent females caused by bacterial strains known to be sensitive to the compound. This oral formulation is administered as a single dose for this therapeutic domain.

For men who are undergoing a prostate biopsy procedure, the medication may be used as a measure to help prevent a bacterial infection that could arise from the procedure. The clinical benefit of this antibiotic is generally seen in treating infections that are located in the urinary tract.

In intravenous (IV) formulations, fosfomycin is a therapeutic option for serious infections, such as those affecting the urinary tract (complicated infections), heart, lungs, blood, and brain. The use of the IV formulation is reserved for situations where other antibacterial agents are deemed unsuitable.

Eligibility for Fosfomicina Kern (Oral)

Official regulatory information strictly defines the patient populations permitted to use Fosfomicina Kern and those for whom use is prohibited or restricted.

---

Populations Permitted or Allowed

Group	Status
Adult Women	Approved for acute, uncomplicated cystitis.
Adolescent Females	Approved for acute, uncomplicated cystitis from 12 years of age.
Adult Men	Approved for antibiotic prophylaxis in transrectal prostate biopsy (EU/EMA indication).

---

Populations for Whom Use is Contraindicated

Fosfomicina Kern is contraindicated and must not be used in several populations as specified in regulatory labeling:

• Patients with documented hypersensitivity or allergy to fosfomycin trometamol or any of the product's non-active components.
• Patients with severe renal impairment defined as creatinine clearance of less than 10 ml/min.
• Patients with certain rare hereditary metabolic disorders, such as fructose intolerance.
• Children below 12 years of age are not recommended due to a lack of established safety and efficacy data (Use Not Established).

---

Conditional or Restricted Use

Use is highly restricted during pregnancy and lactation and is only permitted if clearly necessary. The oral formulation is not indicated for complicated urinary tract infections, such as pyelonephritis.

Interactions with other medicines and products

Official regulatory documents describe clinically significant interactions involving substances that affect gastrointestinal motility, oral anticoagulants, and live bacterial vaccines.

Interacting Product Category	Official Constraint and Mechanism
Drugs Increasing GI Motility	Concomitant administration with drugs like metoclopramide should be avoided. These agents increase movement in the stomach and intestines, which lowers the serum concentration and urinary excretion of fosfomycin, potentially reducing its therapeutic effect. Other prokinetics may have similar effects.
Food and Timing	Administration with food lowers the rate of absorption, resulting in decreased peak concentrations in both serum and urine. While the total amount excreted in the urine may be similar, it is recommended to take the product on an empty stomach (approximately 2–3 hours after a meal) to optimize the rate of absorption.
Oral Anticoagulants	The risk of increased bleeding may be elevated when this product is used with oral anticoagulants. Antibiotics in general may alter the body’s ability to prevent blood clotting, and patients on this combination require careful monitoring.
Live Bacterial Vaccines	Coadministration with live bacterial vaccines, such as Cholera vaccine, live, is not recommended. Systemic antibiotics may reduce the effectiveness of these vaccines through pharmacodynamic antagonism. Vaccination should be spaced at least 14 days after completing antibiotic therapy.

Molecular Action: Irreversible Inhibition of MurA

The mechanism of fosfomycin begins when the active ingredient is actively transported into the bacterial cell, utilizing existing nutrient pathways, specifically the GlpT and UhpT systems. Once inside, the molecule targets the bacterial enzyme MurA (UDP-N-acetylglucosamine-enolpyruvyltransferase) . Acting as a structural mimic of the natural substrate phosphoenolpyruvate ( PEP), fosfomycin executes an irreversible inactivation of MurA by forming a permanent covalent bond with the Cysteine 115 residue in the enzyme's active site. This molecular blockade prevents the initial reaction in the bacterial peptidoglycan pathway.

---

Physiological Consequence: Cell Wall Disruption and Bactericidal Effect

The permanent inactivation of MurA immediately halts the production of peptidoglycan precursors—the molecular building blocks necessary for constructing the rigid bacterial cell wall. The resulting structural compromise means that actively multiplying bacteria are unable to maintain their structural integrity against normal osmotic pressure. This structural failure leads to the physical lysis (rupture) of the bacterial cell, resulting in the drug's core bactericidal physiological effect.

Fosfomicina Kern is designed primarily for oral administration using the trometamol granule formulation, though the active substance is also available as a disodium salt for intravenous (IV) infusion in systemic infections. The standard regimen for uncomplicated acute cystitis is a single dose of 3 grams of fosfomycin. To ensure optimal absorption, the granules must be fully dissolved by stirring in approximately 90 to 120 mL of cold water and consumed immediately after preparation; the powder must not be swallowed in dry form. The oral solution should be taken on an empty stomach, ideally before bedtime after the patient has emptied their bladder.

For the purpose of prophylaxis against bacterial infection during a transrectal prostate biopsy, the regimen involves a two-dose schedule, administered before and 24 hours after the procedure. The use patterns vary significantly for the IV formulation, which is reserved for serious, systemic infections. For IV use, the typical daily dose is between 12 and 24 grams, administered in two to four divided doses, with the individual infusion duration varying based on the dose, such as an 8 g dose requiring at least 60 minutes. Dosage modification is required for patients with renal impairment, requiring reduced doses for IV administration and generally advising against the oral form in cases of severe kidney function decline (CrCl < 10 mL/min). The oral formulation is not indicated for patients under 12 years of age.

Research Evidence / Overview of Studies for Fosfomicina Kern

This overview describes the official research and clinical trials that have been conducted for the medicine's approved uses. This summary focuses on the type of studies available and the nature of the findings reported, without giving any clinical advice or making claims about personal outcomes.

---

Research Evidence for Uncomplicated Acute Cystitis

The evidence base for this use includes Randomized Controlled Trials (RCTs) and Meta-Analyses. Research explored the use of a single-dose oral regimen in non-pregnant adult women and adolescent females experiencing acute, uncomplicated infections of the bladder.

The research focused on measuring two main axes of outcomes: Clinical Resolution/Success, which relates to how symptoms (such as physical discomfort and urinary frequency) changed over defined time intervals; and Microbiological Eradication/Cure, which assesses the presence of the specific infecting bacteria from the urine. Research monitored outcomes related to symptom changes in the observed populations. Regulatory discussions have also noted that some trials described patterns where the initial clearance of bacteria from the urine appeared lower compared to some multi-day comparator treatments. Studies monitored patient-reported outcomes describing perceived discomfort.

Research Evidence for Prophylaxis Before Prostate Biopsy

Research here includes a mix of Randomized Controlled Trials (RCTs), Systematic Reviews, and Observational Studies that examined the use of fosfomycin prior to a transrectal prostate biopsy in men.

The studies monitored outcomes related to systemic or functional imbalance, primarily assessing the Infectious Complication Rate post-procedure, which includes events like fever and post-biopsy urinary tract infections (UTIs) during a follow-up period, typically of 30 days. Studies monitored measurements of infectious complication rates in the observed populations. Comparisons were studied across different regimens with varying resistance patterns.

Evidence Gaps and Research Uncertainties

Review of the available evidence highlights several areas where the research is still developing or where certainty remains low. Findings were mixed in historical trials regarding the precise definitions used for clinical success and bacterial cure. This variability affects the direct comparison of findings between studies. Studies report on symptom outcomes and also suggest differences in early microbiological eradication rates relative to multi-day regimens. Research into its impact on bacterial populations over time continues. Data for certain complex patient populations or those with multiple risk factors is limited, and research is ongoing to fully characterize the medicine's use in these scenarios.

Common questions about Fosfomicina Kern (FAQ)

Q: What is the difference between Fosfomycin and Fosfomicina Kern?

A: Fosfomycin is the active substance, the core drug component that works to fight bacteria. Fosfomicina Kern is the trade name for a specific commercial medicinal product containing the active substance fosfomycin trometamol, manufactured by Kern Pharma, S.L. The name distinguishes the specific product from the general drug substance.

Q: Is Fosfomicina Kern the same as Monurol?

A: Fosfomicina Kern and Monurol are different trade names for medicinal products that contain the same active ingredient, fosfomycin trometamol. Both products use the same drug substance to treat approved infections.

Q: Why do doctors prescribe Fosfomicina Kern when other antibiotics haven't worked?

A: Official information notes that fosfomycin has a unique mechanism of action compared to many other types of antibiotics. This unique way of working, which targets a specific bacterial enzyme, may be active against certain organisms that have developed resistance to other drug classes.

Q: Why is this medicine sometimes prescribed instead of ciprofloxacin?

A: Regulatory documents and related discussions mention that increasing resistance rates to other common treatments for urinary tract infections (UTIs), such as ciprofloxacin, have been noted. This trend has led to a re-evaluation of drugs like fosfomycin for treating uncomplicated UTIs.

Q: How quickly does Fosfomicina Kern typically start working?

A: Pharmacokinetic studies, which track how the body handles the drug, indicate that peak concentrations of fosfomycin in the urine are typically reached within two to four hours after a single oral dose. The concentration in the urine is where the drug primarily works to fight the infection.

Q: How long after taking Fosfomicina Kern should the infection feel better?

A: Information provided to patients in regulatory-linked documents suggests that symptoms related to the infection should begin to show improvement within two to three days after taking the medicine. If symptoms do not noticeably improve or if they worsen, regulatory guidance notes the need for a healthcare review.

Q: Is it normal to feel tired after taking Fosfomicina Kern?

A: Official safety documents list general weakness (asthenia), which is often described as feeling tired or lacking energy, as a common side effect of the medicine.

Q: Does Fosfomicina Kern interact with birth control pills?

A: Official drug interaction information notes a moderate interaction with drugs containing estrogens, which includes combined oral contraceptives. Regulatory information suggests that a healthcare provider should be consulted regarding the use of this medicine alongside oral contraceptives.

Q: Can you drink alcohol while taking Fosfomicina Kern?

A: Official warnings suggest limiting alcoholic beverages while using the product, as alcohol may increase the risk of dizziness, which is a potential side effect. This is noted due to the potential for increased central nervous system effects.

Q: Is Fosfomicina Kern safe to use during pregnancy?

A: Regulatory information specifies that the drug should be used during pregnancy only if clearly needed. This restriction is noted because adequate and well-controlled studies in pregnant women are not available.

Q: Is there a version of Fosfomicina Kern for children?

A: The oral formulation of Fosfomicina Kern is not indicated for patients under 12 years of age. However, different formulations of the active substance fosfomycin (such as the intravenous form used for serious infections) may have established dosing regimens for children younger than 12, as described in some clinical guidelines.

Q: What happens if I take Fosfomicina Kern and I'm allergic to penicillin?

A: Regulatory information indicates there is generally no cross-reactivity between fosfomycin and other classes of antibacterial agents like beta-lactams (penicillin). Fosfomycin belongs to a completely different chemical class, meaning a penicillin allergy does not necessarily imply an allergy to this medicine.

Q: Is it common to get a yeast infection after taking Fosfomicina Kern?

A: Vaginal inflammation or infection (vaginitis), often due to yeast, is listed in official documents as a common side effect of the medicine. This is a common effect seen with many antibiotics.

Q: How do I know if the Fosfomicina Kern worked for my infection?

A: Patient information states that symptoms should show improvement within two to three days of taking the single dose. If symptoms do not noticeably improve or if they get worse, regulatory guidance notes that a healthcare provider should be consulted.

Q: Is Fosfomicina Kern used for long-term or recurring infections?

A: The approved indication for the oral form is for a single-dose treatment of acute, uncomplicated cystitis. Official labels state the oral formulation is not indicated for complicated urinary tract infections, and its approved use is for a single dose.

Q: Is Fosfomicina Kern a broad-spectrum or narrow-spectrum antibiotic?

A: Fosfomycin tromethamine is classified in regulatory-linked documents as a broad-spectrum bactericidal antibiotic. This classification indicates it is active against a wide range of bacteria, including various Gram-positive and Gram-negative organisms.

Q: What if I experience unusual pain after taking the medicine?

A: Regulatory safety information advises patients to seek medical care immediately if they develop severe reactions, such as those related to a serious allergic response. Official documents list symptoms like severe diarrhea, abdominal pain/cramping, or new or worsening bladder symptoms that may require a healthcare review.

Q: Is it possible to be resistant to Fosfomicina Kern?

A: Scientific information confirms that mechanisms for bacterial resistance to fosfomycin, such as those caused by changes in the bacteria's transport systems, have been described and observed in bacteria.

Q: Is it common for people to throw up after taking Fosfomicina Kern?

A: Nausea is listed as a Common side effect in official safety documents. Vomiting is also listed, though it is usually classified as an Infrequent adverse reaction.

Storage and Disposal Requirements

Fosfomicina Kern granules generally do not require any special storage conditions for the unopened sachet, though some labels specify storage below 30 C in the original package. Regardless of the temperature, the product must be stored out of sight and reach of children.

The medicine must not be used after the expiry date shown on the packaging.

Critically, once the granules are dissolved in water to create the oral solution, it must be administered immediately and not stored due to rapid stability loss.

For disposal, the regulatory guidelines instruct that the medicine must not be thrown away via wastewater or household waste. All packaging and any unused or expired product should be returned to a pharmaceutical waste collection point in a pharmacy for proper environmental protection.